Therapeutic potential of combination therapy of soluble VEGF receptor 1 and conventional chemotherapy for ovarian cancer growth

Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature

(2018) Melissa Brackmann et al.   BMC CANCER

Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients

(2018) Venus Dalal et al.   CLINICA CHIMICA ACTA

Angiogenesis Inhibitors for the Treatment of Ovarian Cancer

(2018) Haihong Wang et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Soluble Flt-1 Has Cytotoxic Effects on BeWo Choriocarcinoma Cells

(2017) Michiko Yamashita et al.   Reproductive Sciences

sFLT-1 inhibits proliferation, migration, and invasion of colorectal cancer SW480 cells through vascular mimicry formation suppression

(2017) Wang Jinjun et al.   TUMOR BIOLOGY

The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I–II

(2016) INGIRIDUR SKIRNISDOTTIR et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells

(2016) Tatsuya Miyake et al.   Scientific Reports

Cisplatin resistance in human cervical, ovarian and lung cancer cells

(2015) Jianli Chen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Endothelial dysfunction and preeclampsia: role of oxidative stress

(2014) Lissette C. Sánchez-Aranguren et al.   Frontiers in Physiology

Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model

(2010) K. Kumasawa et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Functional significance of VEGFR-2 on ovarian cancer cells

(2008) Whitney A. Spannuth et al.   INTERNATIONAL JOURNAL OF CANCER